



Oncternal Therapeutics to Present at Stifel Healthcare Conference

November 11, 2019

SAN DIEGO--(BUSINESS WIRE)--Nov. 11, 2019-- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 10:20 a.m. ET / 7:20 a.m. PT.

A live webcast of the presentation will be available online via a link from the [investor relations page](#) of the Company's website at www.oncternal.com, and the webcast will be archived there for at least 30 days following the event.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes [cirtuzumab](#), an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and [TK216](#), an investigational small-molecule compound that is designed to inhibit E26 transformation specific (ETS) family oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a [CAR-T](#) therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at www.oncternal.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20191111005083/en/>

Source: Oncternal Therapeutics, Inc.

Investors

Richard Vincent
858-434-1113
rvincent@oncternal.com

Media

Jason Spark
619-849-6005
jason@canalecomm.com